Use of the Therapeutic Footwear Benefit Among Diabetic Medicare Beneficiaries in Three States, 1995
- Jonathan R Sugarman, MD, MPH,
- Gayle E Reiber, PHD, MPH,
- Greg Baumgardner, MS,
- Cecilia M Prela, PHARMD and
- Joseph Lowery, PHD
- PRO-West Region X, Seattle, Washington
- Department of Family Medicine, University of Washington School of Medicine Region X, Seattle, Washington
- Department of Epidemiology, University of Washington School of Public Health and Community Medicine Region X, Seattle, Washington
- Department of Health Services, University of Washington School of Public Health and Community Medicine Region X, Seattle, Washington
- Health Services Research and Development, VA Puget Sound Health Care System Region X, Seattle, Washington
- Health Care Financing Administration Region X, Seattle, Washington
- Address correspondence and reprint requests to Jonathan R. Sugarman, MD, MPH, PRO-West, 10700 Meridian Ave. N., Suite 100, Seattle WA 98133–9075. E-mail: wapro.jsugarma{at}sdps.org.
Abstract
OBJECTIVE To determine the extent to which Medicare provided reimbursement for therapeutic footwear to diabetic Medicare beneficiaries in Washington, Alaska, and Idaho in 1995.
RESEARCH DESIGN AND METHODS Using inpatient, outpatient, and durable medical equipment claims data, we selected a cohort of diabetic Medicare beneficiaries. Therapeutic footwear claims were identified using a set of billing codes intended only for the diabetes footwear benefit. People at “high risk” or “possibly increased risk” for foot problems who might benefit from therapeutic footwear were identified using a combination of International Classification of Diseases, Ninth Revision, Clinical Modification (1CD-9-CM) diagnostic codes in any of the databases.
RESULTS Among 608,804 beneficiaries, 10.2% (62,170) met the inclusion criteria for diabetes. Of the diabetic beneficiaries, 13.0% (8,079) had at least one “high risk” diagnosis, and 14.0% (8,686) had at least one “possibly increased risk” diagnosis. The percentage of diabetic beneficiaries with therapeutic footwear claims was 2.9% among those with diagnoses high risk, 0.7% among those with diagnoses indicating possibly increased risk, and 0.1% among those with no diagnosis from the list. Altogether, only 0.6% of beneficiaries meeting the diabetes case ascertainment criteria had a therapeutic footwear claim in 1995.
CONCLUSIONS Few diabetic Medicare beneficiaries in Washington, Alaska, and Idaho had claims for reimbursement for therapeutic footwear in 1995. The low utilization of the footwear benefit may represent an important opportunity to improve care for Medicare beneficiaries with diabetes. Further work should be done to characterize the use of the benefit in other regions and to assess whether the low level of usage reflects underutilization.
- Received August 13, 1997.
- Revision received February 4, 1998.
- Accepted February 4, 1998.
- Copyright © 1998 by the American Diabetes Association











